Join Us for a Conversation on the Business of Longevity

On Oct. 12, the Harvard researcher and biotech company founder David Sinclair talks with Andrew Ross Sorkin about the quest for immortality.

Advertisement

Continue reading the main story

Supported by

Continue reading the main story

Image

Credit…

Why has the idea of immortality (or at least living much longer) inspired billions in investment? Harvard researcher and biotech founder David Sinclair joins Andrew Ross Sorkin and the DealBook team to discuss the realities of reversing aging and the implications of extending life for our society.
Presented by

Billions of dollars are being invested in the idea of immortality — or, at least, living much longer than we do today.

Where is the money going in this fast-growing field? What are the realities of altering the aging process? What are the larger implications of extending life for society, business and the environment? On Oct. 12 at 1 p.m. Eastern time, join Andrew Ross Sorkin and DealBook reporter Lauren Hirsch to discuss these questions and more with the leading Harvard researcher and biotech company founder David Sinclair.

This is the second installment of our new DealBook Dialogue virtual series. Submit your questions when you R.S.V.P., or live during the event.

We’re looking forward to hearing your thoughts and seeing you there.

Leave a Reply